[1]
|
Fornetti, J., Welm, A.L. and Stewart, S.A. (2018) Understanding the Bone in Cancer Metastasis. Journal of Bone and Mineral Research, 33, 2099-2113. https://doi.org/10.1002/jbmr.3618
|
[2]
|
Coleman, R.E. (2001) Metastatic Bone Disease: Clinical Features, Pathophysiology and Treatment Strategies. Cancer Treatment Reviews, 27, 165-176. https://doi.org/10.1053/ctrv.2000.0210
|
[3]
|
Plunkett, T.A., Smith, P. and Rubens, R.D. (2000) Risk of Complications from Bone Metastases in Breast Cancer. Implications for Management. European Journal of Cancer, 36, 476-482.
https://doi.org/10.1016/S0959-8049(99)00331-7
|
[4]
|
Niu, Y., Lin, Y., Pang, H., et al. (2019) Risk Factors for Bone Metastasis in Patients with Primary Lung Cancer: A Systematic Review. Medicine (Baltimore), 98, e14084. https://doi.org/10.1097/MD.0000000000014084
|
[5]
|
麦家杰, 张金山, 李志钊, 等. 血清碱性磷酸酶、Ca2+水平在肺癌早期骨转移诊断中的临床意义[J]. 中国中西医结合影像学杂志, 2019, 17(5): 484-488.
|
[6]
|
Duda, D.G. (2017) New Perspective on the Treatment of Intractable Gastrointestinal Cancers: Role of Combination Therapies. The Keio Journal of Medicine, 66, 72. https://doi.org/10.2302/kjm.66-006-ABST
|
[7]
|
D’Antonio, C., et al. (2014) Bone and Brain Metastasis in Lung Cancer: Recent Advances in Therapeutic Strategies. Therapeutic Advances in Medical Oncology, 6, 101-114. https://doi.org/10.1177/1758834014521110
|
[8]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[9]
|
García-Mulero, S., Alonso, M.H., Pardo, J., et al. (2020) Lung Metastases Share Common Immune Features Regardless of Primary Tumor Origin. The Journal for ImmunoTherapy of Cancer, 8, e000491.
https://doi.org/10.1136/jitc-2019-000491
|
[10]
|
Baschuk, N., Rautela, J. and Parker, B.S. (2015) Bone Specific Immunity and Its Impact on Metastasis. BoneKEy Reports, 4, 665. https://doi.org/10.1038/bonekey.2015.32
|
[11]
|
Shiozawa, Y., Pedersen, E.A., Havens, A.M., et al. (2011) Human Prostate Cancer Metastases Target the Hematopoietic Stem Cell Niche to Establish Footholds in Mouse Bone Marrow. Journal of Clinical Investigation, 121, 1298-1312.
https://doi.org/10.1172/JCI43414
|
[12]
|
Ell, B. and Kang, Y. (2012) SnapShot: Bone Metastasis. Cell, 151, 690-690.e1.
https://doi.org/10.1016/j.cell.2012.10.005
|
[13]
|
Roodman, G.D. (2004) Mechanisms of Bone Metastasis. The New England Journal of Medicine, 350, 1655-1664.
https://doi.org/10.1056/NEJMra030831
|
[14]
|
Mundy, G.R. (2002) Metastasis to Bone: Causes, Consequences and Therapeutic Opportunities. Nature Reviews Cancer, 2, 584-593. https://doi.org/10.1038/nrc867
|
[15]
|
Delea, T., Langer, C., McKiernan, J., et al. (2004) The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung Cancer. Oncology, 67, 390-396. https://doi.org/10.1159/000082923
|
[16]
|
Chirgwin, J.M. and Guise, T.A. (2000) Molecular Mechanisms of Tumor-Bone Interactions in Osteolytic Metastases. Critical ReviewsTM in Eukaryotic Gene Expression, 10, 159-178.
https://doi.org/10.1615/CritRevEukarGeneExpr.v10.i2.50
|
[17]
|
Deutsch, A. and Resnick, D. (1980) Eccentric Cortical Metastases to the Skeleton from Bronchogenic Carcinoma. Radiology, 137, 49-52. https://doi.org/10.1148/radiology.137.1.7422860
|
[18]
|
Hendrix, R.W., Rogers, L.F. and Davis, T.M. (1991) Cortical Bone Metastases. Radiology, 181, 409-413.
https://doi.org/10.1148/radiology.181.2.1924781
|
[19]
|
Miric, A., Banks, M., Allen, D., et al. (1998) Cortical Metastatic Lesions of the Appendicular Skeleton from Tumors of Known Primary Origin. Journal of Surgical Oncology, 67, 255-260.
https://doi.org/10.1002/(SICI)1096-9098(199804)67:4<255::AID-JSO9>3.0.CO;2-7
|
[20]
|
Miki, T., Yano, S., Hanibuchi, M., et al. (2004) Parathyroid Hormone-Related Protein (PTHrP) Is Responsible for Production of Bone Metastasis, but Not Visceral Metastasis, by Human Small Cell Lung Cancer SBC-5 Cells in Natural Killer Cell-Depleted SCID Mice. International Journal of Cancer, 108, 511-515. https://doi.org/10.1002/ijc.11586
|
[21]
|
Muguruma, H., Yano, S., Kakiuchi, S., et al. (2005) Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity. Clinical Cancer Research, 11, 8822-8828.
https://doi.org/10.1158/1078-0432.CCR-05-1335
|
[22]
|
Iguchi, H., Tanaka, S., Ozawa, Y., et al. (1996) An Experimental Model of Bone Metastasis by Human Lung Cancer Cells: The Role of Parathyroid Hormone-Related Protein in Bone Metastasis. Cancer Research, 56, 4040-4043.
|
[23]
|
Lorch, G., Gilmore, J.L., Koltz, P.F., et al. (2007) Inhibition of Epidermal Growth Factor Receptor Signalling Reduces Hypercalcaemia Induced by Human Lung Squamous-Cell Carcinoma in Athymic Mice. British Journal of Cancer, 97, 183-193. https://doi.org/10.1038/sj.bjc.6603828
|
[24]
|
Yang, J. and Weinberg, R.A. (2008) Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis. Developmental Cell, 14, 818-829. https://doi.org/10.1016/j.devcel.2008.05.009
|
[25]
|
Thiery, J.P., Acloque, H., Huang, R.Y. and Nieto, M.A. (2009) Epithelial-Mesenchymal Transitions in Development and Disease. Cell, 139, 871-890. https://doi.org/10.1016/j.cell.2009.11.007
|
[26]
|
Guise, T.A. (2002) The Vicious Cycle of Bone Metastases. Journal of Musculoskeletal and Neuronal Interactions, 2, 570-572.
|
[27]
|
Von Moos, R., Strasser, F., Gillessen, S. and Zaugg, K. (2008) Metastatic Bone Pain: Treatment Options with an Emphasis on Bisphosphonates. Supportive Care in Cancer, 16, 1105-1115. https://doi.org/10.1007/s00520-008-0487-0
|
[28]
|
Akob, T., Tesfamariam, Y.M., Macherey, S., Kuhr, K., Adams, A., Monsef, I., Heidenreich, A. and Skoetz, N. (2020) Bisphosphonates or RANK-Ligand-Inhibitors for Men with Prostate Cancer and Bone Metastases: A Network Meta-Analysis. Cochrane Database of Systematic Reviews, 12, CD013020.
https://doi.org/10.1002/14651858.CD013020.pub2
|
[29]
|
Santini, D., Galluzzo, S., Zoccoli, A., Pantano, F., Fratto, M., Vincenzi, B., Lombardi, L., Gucciardino, C., Silvestris, N., Riva, E., et al. (2010) New Molecular Targets in Bone Metastases. Cancer Treatment Reviews, 36, S6-S10.
https://doi.org/10.1016/S0305-7372(10)70013-X
|
[30]
|
Russell, R.G.G. (2007) Bisphosphonates: Mode of Action and Pharmacology. Pediatrics, 119, S150-S162.
https://doi.org/10.1542/peds.2006-2023H
|
[31]
|
Smith, H.A. and Kang, Y. (2013) The Metastasis-Promoting Roles of Tumor-Associated Immune Cells. Journal of Molecular Medicine, 91, 411-429. https://doi.org/10.1007/s00109-013-1021-5
|
[32]
|
De Groot, A., Appelman-Dijkstra, N., van der Burg, S. and Kroep, J. (2018) The Anti-Tumor Effect of RANKL Inhibition in Malignant Solid Tumors—A Systematic Review. Cancer Treatment Reviews, 62, 18-28.
https://doi.org/10.1016/j.ctrv.2017.10.010
|
[33]
|
Simatou, A., Sarantis, P., Koustas, E., Papavassiliou, A.G. and Karamouzis, M.V. (2020) The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL. International Journal of Molecular Sciences, 21, 7570. https://doi.org/10.3390/ijms21207570
|